Amivantamab vs Pamvatamig

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR x c-MET · full Non-Small Cell Lung Cancer pipeline

Amivantamab

Marketed by Johnson & Johnson and partners

Approved in Non-Small Cell Lung Cancerbispecific antibody
Partial signal

NCT04487080 · Phase 3 · active, not recruiting

This was a randomized phase 3 trial of 1,074 people with an active comparator (osimertinib) and a hard progression-free survival endpoint that was clearly met. The amivantamab plus lazertinib arm was open-label; only the osimertinib and lazertinib-alone arms were blinded, so the main comparison was not blinded.

Next expected readout: December 2026 · NCT06816992 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results. (met)

Result source: NCT04487080

Pamvatamig

Developed by Genmab and partners

Phase 2 in Non-Small Cell Lung Cancerbispecific antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2028 · NCT06885840 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAmivantamabPamvatamig
PFS, median23.7 vs 16.6vs Osimertinibn 429NCT04487080
4 other results
—Not reported
OS, median—Trial running · NCT07100080—Not reported
ORR—Trial running · NCT07100080—Not reported
Duration of response, median—Trial running · NCT07100080—Not reported

PFS, median

Amivantamab
23.7 vs 16.6vs Osimertinibn 429NCT04487080
4 other results
Pamvatamig
—Not reported

OS, median

Amivantamab
—Trial running · NCT07100080
Pamvatamig
—Not reported

ORR

Amivantamab
—Trial running · NCT07100080
Pamvatamig
—Not reported

Duration of response, median

Amivantamab
—Trial running · NCT07100080
Pamvatamig
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Pamvatamig: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Amivantamab: 3 of 4 rows · Pamvatamig: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAmivantamab
Dropout rate
78.1%Experimental: Arm A (Open-label): a
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 4 more results
75%Experimental: Arm C (Double-blind)
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
81.7%
NCT04538664 · Phase 3 · combination
74.5%Main Study: Arm A: Lazertinib + Am
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
80.2%Main Study: Arm C: Amivantamab + C
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs
—Experimental: Arm A (Open-label): a
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 4 more results
—Experimental: Arm C (Double-blind)
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—
NCT04538664 · Phase 3 · combination
—Main Study: Arm A: Lazertinib + Am
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—Main Study: Arm C: Amivantamab + C
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Serious AEs
48.7%Experimental: Arm A (Open-label): a
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 4 more results
35.2%Experimental: Arm C (Double-blind)
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
37.1%
NCT04538664 · Phase 3 · combination
52.1%Main Study: Arm A: Lazertinib + Am
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
32.3%Main Study: Arm C: Amivantamab + C
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs
a
paronychia 68.4%
infusion related reaction 62%
rash 61.8%
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 4 more results
rash 44.6%
diarrhoea 31.9%
paronychia 28.6%
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
neutropenia 58.3%
paronychia 56.3%
rash 53.6%
NCT04538664 · Phase 3 · combination
neutropenia 65.8%
thrombocytopenia 59.3%
infusion related reaction 54%
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
infusion related reaction 56.9%
neutropenia 56.2%
nausea 44.6%
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Amivantamab

PFS 23.72 vs 16.59 Osimertinib months
time to event · months
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 4 more results
18.46 vs 16.59 Osimertinib months
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
11.37 vs 6.7 Chemotherapy Alone months
NCT04538664 · Phase 3 · combination
8.31 vs 4.17 Carboplatin + Pemetrexed months
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
6.28 vs 4.17 Carboplatin + Pemetrexed months
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Amivantamab's landscape · Pamvatamig's landscape